October 20, 2026 09:53 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Operation completed’: Tiger Shroff shooters allegedly alerted handlers after firing, probe reveals | 'I don't mind saying sorry 1,000 times': Sonu Nigam apologises to Kannadigas over ‘Pahalgam’ remark amid concert ban demand | After Vijay, is Dhanush eyeing politics? TVK calls Thalapathy an inspiration | Trump Says Paris Will Become ‘Muslim City Very Soon’, Blames Macron’s Immigration Policies | Four killed in fresh Manipur violence as protesters take bodies to Chief Minister’s residence | Tiger Shroff firing: Three accused arrested on train in Rajasthan, suspected Bishnoi gang link emerges | 'Internet access a fundamental right for children': SC rejects age-based 'blanket' ban | 'We will fight our own government': RG Kar victim's father threatens fresh protest after Sandip Ghosh gets bail | RG Kar shocker: Sandip Ghosh gets bail as only 7 of 147 witnesses examined, junior doctor blasts CBI | Trump waives Russia-related sanctions

Lupin launches generic Aricept tablets in the US

| | Mar 31, 2016, at 09:23 pm
Mumbai/ Baltimore, Mar 31 (IBNS) Mumbai-based Lupin Limited (Lupin), a transnational pharmaceutical company producing and developing a wide range of branded and generic formulations, biotechnology products and APIs globally, announced on Thursday that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Donepezil Hydrochloride Tablets, 23 mg having received approval from the United States Food and Drug Administration (FDA) earlier to market a generic equivalent of Eisai Inc's Aricept® Tablets, 23mg.
Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. works in the area of generic medicines and branded formulations.
 
Lupin's Donepezil Hydrochloride Tablets, 23 mg are the AB rated generic equivalent of Eisai Inc's Aricept® Tablets, 23mg. It is indicated for the treatment of dementia of the Alzheimer's type.
 
Aricept® had US sales of USD 47.1 million (IMS MAT December 2015).

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.